PULMONARY MEDICATIONS

MATT KRIEBS, APRN, FNP-BC

NOVEMBER 1, 2024




• FOCUS ON ASSESSMENT AND PHARMACOLOGIC THERAPIES FOR COMMON CONDITIONS LIKE OBSTRUCTIVE LUNG DISEASE, COPD, ASTHMA

• WILL TOUCH BRIEFLY ON COVID MANAGEMENT AS WELL.

HISTORICAL PERSPECTIVE My, how far we've come!





CONTAINS 2 O CIGARETTES

Northrop&Lyman Co. Limited Toronto Canada

OBSTRUCTIVE LUNG DISEASE

1

ASTHMA-

REVERSIBLE NARROWING OF THE AIRWAYS MARKED BY SMOOTH MUSCLE HYPERREACTIVITY AND INCREASED MUCUS PRODUCTION

A. F.

COPD-

IRREVERSIBLE LOSS OF LUNG FUNCTION.

-

THREE BROAD TYPES OF MEDICATIONS

Beta Agonists-SABA and LABA

a star

A SHALL AND A SHALL AND


A. F.

Inhaled Corticosteroids-ICS Muscurinic Antagonists-SAMA and LAMA

the last

Respiratory Treatments Rescue meds Maintenance meds

SABA ICS LAMA PDE4 Inhibitor Combo meds Biologics Leukotriene Modifiers



ASSESSMENT

- SPIROMETRY
- CLINICAL INDICATORS GOLD
- AMERICAN LUNG ASSOCIATION RULE OF TWOS
- GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE GOLD ABE

al at

Sec.


• MODIFIED MRC – DYSPNEA SCALE

A. F.

- COPD ASSESSMENT TEST CAT ASSESSMENT
- COPD ETIOTYPES

SPIROMETRY

STANDARD ASSESSMENT – NOT ALWAYS FEASIBLE



A St.

No. Carlo Ala

Image Source: https://goldcopd.org/gold-teaching-slide-set/

Role of Spirometry in COPD

Figure 2.6

a second

- Diagnosis
- Assessment of severity of airflow obstruction (for prognosis)
- Follow-up assessment
- Therapeutic decisions
 - Pharmacological in selected circumstances (e.g., discrepancy between spirometry and level of symptoms)
 - Consider alternative diagnoses when symptoms are disproportionate to degree of airflow obstruction
 - Non-pharmacological (e.g., interventional procedures)
- Identification of rapid decline

Image Source: https://goldcopd.org/gold-teaching-slide-set/

CLINICAL INDICATORS

- FIRST SUSPICION OF COPD BASED ON SYMPTOMS
- ALSO CONSIDER RISK FACTORS INCLUDING SMOKING (FIRST AND SECOND HAND), OCCUPATIONAL EXPOSURE, ALPHA-1 ANTITRYPSIN DEFICIENCY, ETC.

Clinical Indicators for Considering a Diagnosis of COPD

Figure 2.1

Image Source: https://goldcopd.org/gold-teaching-slide-set/

Consider the diagnosis of COPD, and perform spirometry, if any of these clinical indicators are present: (these indicators are not diagnostic themselves, but the presence of multiple key indicators increases the probability of the presence of COPD; in any case, spirometry is required to establish a diagnosis of COPD)

Dyspnea that is	Progressive over time Worse with exercise Persistent
Recurrent wheeze	
Chronic cough	May be intermittent and may be non-productive
Recurrent lower respiratory tract infections	
History of risk factors	Tobacco smoke (including popular local preparations) Smoke from home cooking and heating fuels Occupational dusts, vapors, fumes, gases and other chemicals Host factors (e.g., genetic factors, developmental abnormalities, low birthweight, prematurity, childhood respiratory infections etc.)

RULE OF TWOS QUICK ASTHMA ASSESSMENT

American Lung Association.

1. Baylor College of Medicine's Rules of Two®

- Do you have asthma symptoms or use your quick-relief inhaler more than two times per week?
- Do you awaken at night with symptoms more than two times per month?
- Do you refill your quick-relief inhaler more than two times per year?

If you answer "yes" to one or more questions, your asthma may not be well controlled. Plan a visit with your healthcare provider and share your results.

GOLD ABE


CONFIRM DIAGNOSIS

• ASSESS SYMPTOMS

ASSESS HISTORY/RISK OF EXACERBATION

A. F.

1.6



1997

a second

MODIFIED MRC DYSPNEA SCALE

and an

A St.

Grade	Description of breathlessness
0	I only get breathless with strenuous exercise
1	I get short of breath when hurrying on level ground or walking up a slight hill
2	On level ground, I walk slower than people of the same age because of breathlessness, or have to stop for breath when walking at my own pace
3	I stop for breath after walking about 100 yards [91 meters] or after a few minutes on level ground
4	I am too breathless to leave the house or I am breathless when dressing

and the second

Adapted from: Fletcher CM, Elmes PC, Fairbairn AS, Wood CH. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. Br Med J 1959; 2:257.

COPD ASSESSMENT TOOL

E E

CAT[™] ASSESSMENT

1

For each item below, place a mark (x) in the box that best describes you currently. Be sure to only select one response for each question.

C. P. Star

EXAMPLE: I am very happy	0 2 3 4 5	I am very sad	SCOR
I never cough	012345	I cough all the time	99 1
I have no phlegm (mucus) in my chest at all	012345	My chest is completely full of phlegm (mucus)	
My chest does not feel tight at all	012345	My chest feels very tight	
When I walk up a hill or one flight of stairs I am not breathless	012345	When I walk up a hill or one flight of stairs I am very breathless	
I am not limited doing any activities at home	012345	l am very limited doing activities at home	
I am confident leaving my home despite my lung condition	012345	I am not at all confident leaving my home because of my lung condition	
I sleep soundly	012345	I don't sleep soundly because of my lung condition	37
I have lots of energy	012345	I have no energy at all	

a second

PUTTING IT ALL TOGETHER

6.5



A State of the second second second

and a

Hand.

COPD ETIOTYPES

• VARIOUS TYPES OF COPD MAY RESPOND BETTER/WORSE TO DIFFERENT TREATMENTS

A St.


Classification Description **Genetically determined COPD** Alpha-1 antitrypsin deficiency (AATD) (COPD-G) Other genetic variants with smaller effects acting in combination Early life events, including premature birth and low **COPD** due to abnormal lung development (COPD-D) birthweight, among others **Environmental COPD** Cigarette smoking COPD (COPD-C) • Exposure to tobacco smoke, including in utero or via passive smoking • Vaping or e-cigarette use Cannabis **Biomass and pollution exposure** Exposure to household pollution, ambient air pollution, COPD (COPD-P) wildfire smoke, occupational hazards **COPD** due to infections (COPD-I) Childhood infections, tuberculosis-associated COPD, HIVassociated COPD COPD & asthma (COPD-A) Particularly childhood asthma COPD of unknown cause (COPD-U)

*Adapted from Celli et al. (2022) and Stolz et al. (2022)

Figure <u>1.2</u>

Proposed Taxonomy (Etiotypes) for COPD

GOALS OF COPD TREATMENT



a second

NON-PHARMACOLOGIC MANAGEMENT

- LESS MEDICINE IS ALWAYS BEST
- SMOKING CESSATION IS THE FIRST STEP
 - DON'T FORGET VAPES, MARIJUANA, PIPES, CIGARS
 - SECONDHAND SMOKE
- PROMOTE VACCINATIONS
- PROMOTE PHYSICAL ACTIVITY
- OXYGEN FOR HYPOXEMIC PATIENTS, NONINVASIVE POSITIVE PRESSURE VENTILATION (NPPV) – SHOWN TO REDUCE MORTALITY

A St.

and the

Non-Pharmacological Management of COPD*

Figure 3.12

4

Patient Group	Essential	Recommended	Depending on Local Guidelines
A	Smoking cessation (can include pharmacological treatment)	Physical activity	Influenza vaccination COVID-19 vaccinations Pneumococcal vaccination Pertussis vaccination Shingles vaccination RSV vaccination
B and E	Smoking cessation (can include pharmacological treatment) Pulmonary rehabilitation	Physical activity	Influenza vaccination COVID-19 vaccinations Pneumococcal vaccination Pertussis vaccination Shingles vaccination RSV vaccination

*Can include pharmacological treatment

MANAGEMENT OF COPD

A. F.




Image Source: https://goldcopd.org/gold-teaching-slide-set/

1.6

1997

4-6-A

MEDICATION CLASSES

- BETA AGONISTS
- INHALED CORTICOSTEROIDS
- MUSCARINIC ANTAGONISTS
- PHOSPHODIESTERASE
- SMOKING CESSATION
- ALLERGY MEDICATIONS

A St.

and an

BIOLOGICS

Commonly Used Maintenance Medications in COPD*

Figure 3.18

			DELIVERY OPTIONS		
Generic Drug Name	Inhaler Type	Nebulizer	Oral	Injection	Duration of Action
BETA ₂ -Agonists					
Short-acting (SABA)					
Fenoterol	MDI	✓	pill, syrup		4-6 hours
Levalbuterol	MDI	✓			6-8 hours
Salbutamol (albuterol)	MDI & DPI	✓	pill, syrup, extended	~	4-6 hours
			release tablet		12 hours (ext. release
Terbutaline	DPI		pill	✓	4-6 hours
Long-acting (LABA)					
Arformoterol		 ✓ 			12 hours
Formoterol	DPI	√			12 hours
Indacaterol	DPI				24 hours
Olodaterol	SMI				24 hours
Salmeterol	MDI & DPI				12 hours
Anticholinergics					
Short-acting (SAMA)					
Ipratropium bromide	MDI	✓			6-8 hours
Oxitropium bromide	MDI				7-9 hours
Long-acting (LAMA)					
Aclidinium bromide	DPI				MDI 12 hours
Glycopyrronium bromide	DPI		solution	✓	12-24 hours
Tiotropium	DPI, SMI, MDI		Solution		24 hours
Umeclidinium	DPI				24 hours
Glycopyrronium		 ✓ 			12 hours
Revefenacin					24 hours
Combination Short-Acting Beta ₂ -Agonist P	lus Anticholinor	ric in One De	wice (SABA+SAMA)		24110013
Fenoterol/ipratropium	SMI		AND AND AND AND A		6-8 hours
Salbutamol/ipratropium	SMI, MDI				6-8 hours
Combination Long-Acting Beta ₂ -Agonist Pl			vice (LABA+LAMA)		0-8 110013
Formoterol/aclidinium	DPI		VICE (LADATLAWA)		12 hours
Formoterol/glycopyrronium	MDI				12 hours
Indacaterol/glycopyrronium	DPI				12-24 hours
Vilanterol/umeclidinium	DPI				24 hours
Olodaterol/tiotropium	SMI				24 hours
Methylxanthines	31711				24 110015
			solution	✓	Variable, up to 24 hou
Aminophylline				· √	
Theophylline (SR)			pill	v	Variable, up to 24 hou
Combination of Long-Acting Beta ₂ -Agonis		old in One L	evice (LABA+ICS)		12
Formoterol/beclometasone	MDI, DPI				12 hours
Formoterol/budesonide	MDI, DPI				12 hours
Formoterol/mometasone	MDI				12 hours
Salmeterol/fluticasone propionate	MDI, DPI				12 hours
Vilanterol/fluticasone furoate	DPI				24 hours
Triple Combination in One Device (LABA+					241
Fluticasone/umeclidinium/vilanterol	DPI				24 hours
Beclometasone/formoterol/glycopyrronium	MDI, DPI				12 hours
Budesonide/formoterol/glycopyrrolate	MDI				12 hours
Phosphodiesterase-4 Inhibitors					211
Roflumilast			pill		24 hours
Mucolytic Agents					
Erdosteine			pill		12 hours
Carbocysteine [†]			pill		
N-acetylcysteine [†]		1	pill		1

*Not all formulations are available in all countries. In some countries other formulations and dosages may be available. †Dosing regimens are under discussi MDI = metered dose inhaler; DPI = dry powder inhaler; SMI = soft mist inhaler. Note that glycopyrrolate & glycopyrronium are the same compound.

BETA AGONISTS

A St.

• DRUGS:

- SHORT-ACTING (SABA): ALBUTEROL, LEVALBUTEROL
- LONG-ACTING (LABA): SALMETEROL, FORMOTEROL, OLDATEROL
- NEBULIZED MEDS: ALBUTEROL SULFATE (SABA), LEVALBUTEROL (SABA), ARFORMOTEROL/BROVANA (LABA), FORMOTEROL/PERFOROMIST (LABA)
- MECHANISM OF ACTION: STIMULATES THE BETA-2 RECEPTORS IN THE LUNGS AND RELAXES AND DILATES THE SMOOTH MUSCLE
- SIDE EFFECTS: CROSSOVER EFFECT TO BETA-1 RECEPTORS TACHYCARDIA, TREMULOUSNESS

INHALED CORTICOSTEROIDS

• DRUGS: FLUTICASONE, BUDESONIDE

A. F.

- NEBULIZED MEDS: BUDESONIDE/PULMICORT
- MECHANISM OF ACTION: SUPPRESSES THE INFLAMMATORY RESPONSE AND DECREASES MUCOUS IN THE AIRWAY

and the

• SIDE EFFECTS: INCREASED RISK OF PNEUMONIA (RARE), THRUSH, OSTEOPOROSIS, OPEN ANGLE GLAUCOMA, CATARACTS

	US Trade Name	Manufacturer	Dosage Form/Device	Strength	Labeled Uses
	QVAR®	Ivax / 3M	MDI (HFA)	40 mcg/puff 80 mcg/puff	Asthma (age ≥ 5 yrs) - Maintenance - Systemic corticoster reduction
	Vanceril ^{®†}	Schering-Plough	MDI*	42 mcg/puff 84 mcg/puff	Asthma (age ≥ 5 yrs) - Maintenance - Systemicl corticoste reduction
	Pulmicort Turbuhaler®	AstraZeneca	DPI	200 mcg/dose	Asthma (age ≥ 6 yrs) - Maintenance - Systemic corticoster reduction
	Pulmicort Respules [®]	AstraZeneca	Inhalation suspension	500 mcg 1,000 mcg 2,000 mcg	Asthma (age 1-8 yrs)
	AeroBid [®] AeroBid [®] -M	Forest / 3M	MDI* MDI-menthol*	250 mcg/puff	Asthma (age ≥ 6 yrs) - Maintenance - Systemic corticoste reduction
	Bronalide ^{††}	Boehringer Ingelheim (Canada)	MDI*	250 mcg/puff	Asthma (age ≥ 6 yrs) - Maintenance - Systemic corticoste reduction
	Flovent®	GlaxoSmithKline	MDI*	44 mcg/puff 110 mcg/puff 220 mcg/puff	Asthma (age ≥ 12 yrs - Maintenance - Systemic corticoster reduction
	Flovent ^{® TT} Rotadisk	GlaxoSmithKline	DPI – blister pack (4) for use in diskhaler	50 mcg/dose 100 mcg/dose 250 mcg/dose	Asthma (age ≥ 12 yrs - Maintenance - Systemic corticoster reduction
	Flovent [®] Diskus [†]	GlaxoSmithKline	DPI – breath activated inhalation device	50 mcg/dose 100 mcg/dose 250 mcg/dose	Asthma (age ≥ 12 yrs - Maintenance - Systemic corticoster reduction
	Asmanex [®] Twisthaler	Schering-Plough	DPI	220 mcg/dose	Asthma (age ≥ 12 yrs - Maintenance - Systemic corticoste reduction
	Azmacort®	Aventis	MDI* – with spacer mouthpiece	100 mcg/dose	Asthma (age ≥ 6 yrs) - Maintenance - Systemic corticoste reduction

100

INHALED CORTICOSEROIDS

Factors to Consider when Initiating ICS Treatment

Figure 3.21

Factors to consider when adding ICS to long-acting bronchodilators:

(note the scenario is different when considering ICS withdrawal)

STRONGLY FAVORS USE	History of hospitalization(s) for exacerbations of COPD [#] ≥ 2 moderate exacerbations of COPD per year [#] Blood eosinophils ≥ 300 cells/µL History of, or concomitant asthma
FAVORS USE	1 moderate exacerbation of COPD per year [#] Blood eosinophils 100 to < 300 cells/μL
AGAINST USE	Repeated pneumonia events Blood eosinophils < 100 cells/μL History of mycobacterial infection

"despite appropriate long-acting bronchodilator maintenance therapy (see Figures 3.7 & 3.18 for recommendations); *note that blood eosinophils should be seen as a continuum; quoted values represent approximate cut-points; eosinophil counts are likely to fluctuate.

Adapted from & reproduced with permission of the © ERS 2019: European Respiratory Journal 52 (6) 1801219; DOI: 10.1183/13993003.01219-2018 Published 13 December 2018

Image Source: https://goldcopd.org/gold-teaching-slide-set/

MUSCARINIC ANTAGONISTS (ANTICHOLINERGICS)

• DRUGS:

- SHORT-ACTING (SAMA): IPRATROPRIUM BROMIDE
- LONG-ACTING (LAMA): TIOTROPIUM, ACLIDINIUM, UMECLIDINIUM, GLYCOPYRRONIUM
- NEBULIZED MEDS: IPRATROPIUM/ATROVENT (SAMA), REVAFENACIN/YUPELRI (LAMA)
- MECHANISM OF ACTION: BINDS TO THE M1-5 RECEPTORS CAUSING SMOOTH MUSCLE RELAXATION IN THE AIRWAY
- SIDE EFFECTS: DRY MOUTH, HEADACHE, URINARY RETENTION
- OF NOTE: WHEN USING LAMA, AVOID USING SAMA CONCURRENTLY TO PREVENT RECEPTOR COMPETITION

PHOSPHODIESTERASE INHIBITORS

- DRUGS: ROFLUMILAST (SELECTIVE), THEOPHYLLINE (NONSELECTIVE)
- MECHANISM OF ACTION: WORK BY BLOCKING INFLAMMATORY MEDIATORS
- SIDE EFFECTS: GI ISSUES, HEADACHE, WEIGHT LOSS, DEPRESSION, ANXIETY
- WHEN TO USE? ADD-ON WHEN TRIPLE THERAPY IS NOT EFFECTIVE IN PREVENTING EXACERBATION OR HOSPITALIZATION

STEROIDS

• DRUGS: PREDNISONE, MEDROL, DECADRON

 MECHANISM OF ACTION: SYSTEMICALLY REDUCES INFLAMMATORY CYTOKINES, REDUCES EOSINOPHILS IN THE LUNGS, UPREGULATES PROTEINS THAT REDUCE PROSTAGLANDIN AND LEUKOTRIENE SYNTHESIS

Side effects:

Upper body obesity with thin arms and legs

- Buffalo Hump
- Red, Round Face
- High Blood Sugar
- High Blood Pressure
- Vertigo
- Blurry Vision
- Acne
- Female Balding
- Water Retention
- Menstrual Irregularities
- Thin Skin and Bruising
- Purple Striae
- Poor Wound Healing
- Hirsutism
- Severe Depression
- Cognitive Difficulties
- Emotional Instability
- Sleep Disorders
- Fatigue

OTHER MEDICATIONS

E St.

- SMOKING CESSATION NICOTINE REPLACEMENT, BUPROPION/ZYBAN, VARENICLINE/CHANTIX
- ALLERGY MEDICATIONS ANTIHISTAMINE PILLS/SPRAYS, NASAL STEROID SPRAY, MONTELUKAST/SINGULAIR
- BIOLOGICS EOSINOPHILIC ASTHMA/IGE LIKELY BEST TO CONSULT AN IMMUNOLOGIST

OTHER MEDICATIONS

E.F.

Other Pharmacological Treatments

Figure 3.22

100

Heren .

 Intravenous augmentation therapy may slow down the progression of emphysema (Evidence B)
 There is no conclusive evidence of a beneficial role of antitussives in people with COPD (Evidence C)
 Vasodilators do not improve outcomes and may worsen oxygenation (Evidence B)
 Low-dose long acting oral and parenteral opioids may be considered for treating dyspnea in COPD patients with severe disease (Evidence B)
 Drugs approved for primary pulmonary hypertension are not recommended for patients with a pulmonary hypertension secondary to COPD (Evidence B)

Image Source: https://goldcopd.org/gold-teaching-slide-set/

METHODS OF ADMINISTRATION

- HANDHELD DEVICES METERED DOSE INHALERS (MDI), BREATH ACTUATED DRY POWDER (I.E.: BREO), HANDHELD MIST (I.E.: COMBIVENT)
- DON'T FORGET THE SPACER! HELPS IMPROVE RESPIRATORY DEPOSITION
- NEBULIZED THERAPY



Image Source: https://aafa.org/asthmamedicine/ipratropium-bromide-albuterolsulfate-combivent-respimat/



Image Source: https://en.wikipedia.org/wiki/Dry-powder_inhaler





Image Source: https://www.drugs.com/



OTHER CONSIDERATIONS


- CONVENIENCE FREQUENCY, NEB VS MDI AS A TIME COMMITMENT
- EXPENSE FORMULARY CONTROLS ALL...
- AVAILABILITY FORMULARY... AGAIN

A St.

• SEVERITY OF DISEASE – PREFER NEBS OR MIST FOR THOSE WITH VERY SEVERE COPD

COVID-19 TREATMENT


A St.



COVID-19 TREATMENT

ANTIVIRALS

MONOCLONAL ANTIBODIES SYMPTOMATIC TREATMENT



COPD AND COVID

A St.

COVID-19 & COPD Figure 6.2 COPD patient Dyspnea & mild COVID-19 ARDS Not infected ARDS Mild constitutional symptoms Fatigue Clinical COPD: 个个 SOB ± hypoxia SIRS/Shock Fever > 37.5 °C, 个 SOB SOB Features **Cardiac Failure** Cough, SOB $PaO_2/FiO_2 \le 300 \text{ mmHg}$ Dry Cough, Fatigue, Diarrhea Cough VTE SARS-CoV-2 PCR CXR/CT, SpO₂ SpO₂ CXR/CT, SpO₂ Lymphopenia Abnormal CRP, LDH, IL-6 Lymphopenia Thrombocytopenia Investigations D-dimer, ferritin CT Chest Thrombocytopenia troponin, BNP CRP, D-dimer D-dimer, PCT Continue Usual COPD Maintenance Therapy Controlled Oxygen NIV, HFNT Protective Strategies, IMV Systemic Steroids Possible COPD Exacerbation Therapy Home Exercise Home exercise Remdesivir Prone positioning Interventions Protective Strategies Low intensity exercise PR Anticoagulation Anticoagulation Therapeutic Trials Therapeutic Trials Therapeutic Trials

(ARDS, Adult respiratory distress syndrome; BNP, brain natriuretic peptide; CRP, C reactive protein; CT, computed tomography; CXR, chest radiograph; HFNT, high flow nasal therapy; IL-6, interleukin 6; IMV, invasive mechanical ventilation; LDH, lactate dehydrogenase; NIV, non-invasive ventilation; PCT, procalcitonin; PFT, pulmonary function tests; PR, pulmonary rehabilitation; SOB, Shortness of breath; SpO₂, peripheral oxygen saturation; VTE, venous thromboembolism)

Image Source: https://goldcopd.org/gold-teaching-slide-s

12.20

-

Reprinted with permission of the American Thoracic Society.

Copyright © 2020 American Thoracic Society. All rights reserved.

Halpin et al. 2020. Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: The 2020 GOLD Science Committee Report on COVID-19 & COPD. Published Ahead of Print: https://www.atsjournals.org/doi/abs/10.1164/rccm.202009-3533SO The American Journal of Respiratory and Critical Care Medicine is an official journal of the American Thoracic Society

USE STATISTICS

ANTIVIRALS

• ANTIVIRALS: PAXLOVID

- MECHANISM OF ACTION: BIND TO AMINO ACIDS RESULTING IN FUNCTIONAL INACTIVATION
- NUCLEOSIDE ANALOGS: FAVIPIRAVIR, RIBAVIRIN, REMDESIVIR, MOLNUPORAVIR
 - MECHANISM OF ACTION: INHIBITION OF VIRAL REPLICATION
- **DOWNFALLS: MANY DRUG INTERACTIONS WITH PAXLOVID (LESS WITH MOLNUPORAVIR)**

A St.

Treatment	Who (Among people who are at high risk of getting sick)	When	How
Nirmatrelvir with <u>Ritonavir</u> <u>(Paxlovid)</u> 🗹 Antiviral	Adults; children ages 12 years and older	Start as soon as possible; must begin within 5 days of when symptoms start	Taken at home by mouth (orally)
<u>Veklury</u> <u>(remdesivir)</u> ⊠ Antiviral	Adults and children	Start as soon as possible; must begin within 7 days of when symptoms start	Intravenous (IV) infusions at a healthcare facility for 3 consecutive days
<u>Molnupiravir</u> <u>(Lagevrio)</u> ⊠ Antiviral	Adults	Start as soon as possible; must begin within 5 days of when symptoms start	Taken at home by mouth (orally) v/covid/treatment/index.html

MONOCLONAL ANTIBODIES

• DRUGS:

- BAMLANIVIMAB + ETESEVIMAB
- CASIRIVIMAB + IMDEVIMAB
- SOTROVIMAB
- **REGDANVIMAB**
- TOCILIZUMAB
- SARILUMAB
- MECHANISM OF ACTION: VIRUS BINDING BY S-PROTEIN-SPECIFIC MONOCLONAL ANTIBODIES OR SUPPRESSION OF THE SARS-COV-2 INFECTION INDUCED INFLAMMATION BY IL-6 RECEPTOR INHIBITION

的是"你们不是你的"。我们

Heren .

DOWNFALLS: EXPENSIVE, HARD TO COME BY

A. F.

SYMPTOM MANAGEMENT

- ORAL STEROIDS DECADRON 6MG-12MG FOR 7-10 DAYS
 - ESPECIALLY WITH CRP >12
 - HIGHER CRP = HIGHER DOSE
- NEBULIZED BETA AGONISTS
- INHALED CORTICOSTEROIDS
- EXPECTORANTS MUCINEX 600MG 3-4X DAILY FOR 14 Days
- COUGH MEDICATION TESSALON, ROBITUSSIN
- LABS: CBC/CMP, ESR, CRP, COAGS

E St.

Associated With Severe or Critical Illness

↓	Lymphocytes
•	Lymphocytes

↑ Neutrophils

↑ ALT level

↑ AST level

↑ LDH level

↑ PCT level

↑ CRP level

✦ Ferritin level

✤ Serum levels of proinflammatory cytokines and chemokines

Evidence of immune dysregulation:

 Higher plasma levels of proinflammatory cytokines (TNFα, IL-1, IL-6) and chemokines (IL-8) in severe and critically ill patients vs less severely ill patients

Associated With Mortality

↑ D-dimers

Lymphopenia

Image Source: https://www.acep.org/corona/covid-19-field-guide/assessment/laboratory-abnormalities

WHEN IN DOUBT... CHECK IT OUT! Also known as references

• AMERICAN LUNG ASSOCIATION - HTTPS://WWW.LUNG.ORG/LUNG-HEALTH-DISEASES

E St.

- GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE <u>HTTPS://GOLDCOPD.ORG/</u>
- CENTERS FOR DISEASE CONTROL <u>HTTPS://WWW.CDC.GOV/COPD/PHP/KEY-RESOURCES/INDEX.HTML</u>
- COPD FOUNDATION HTTPS://WWW.COPDFOUNDATION.ORG/PRAXIS/ABOUT-PRAXIS/WHAT-IS-PRAXIS.ASPX

CASE STUDY

- MR. B IS A 67-YEAR-OLD MALE WHO PRESENTS TO THE CLINIC WITH COMPLAINTS OF A 6-MONTH HISTORY OF PROGRESSIVELY WORSENING COUGH WHICH IS PRODUCTIVE OF LIGHT COLORED MUCOUS.
 HE A FARMER AND TELLS YOU HE IS HEALTHY OTHER THAN HTN AND A 60 PACK-YEAR HISTORY OF SMOKING, CURRENTLY HE HAS CUT BACK AND IS SMOKING HALF A PACK PER DAY.
- MR. B. TELLS YOU HE IS ONLY HERE BECAUSE HIS WIFE INSISTED. HIS LAST FOLLOW UP WAS ON HIS 65th BIRTHDAY. HE NOTES NO CHANGE IN HIS HEALTH SINCE THEN, EXCEPT THIS COUGH.
- WHAT STANDS OUT TO YOU?

CASE STUDY - ASSESSMENT

- MR. B REPORTS DYSPNEA GOING UP THE STAIRS, AND NOTES WHEN WALKING ON A FLAT SURFACE, HE IS NOT AS FAST AS MOST PEOPLE BUT NOTES IT DOES NOT INHIBIT HIS ADLS.
 - WHAT IS MR. B'S MMRC?
- HE REPORTS THE COUGH IS PERSISTENT, IT INTERRUPTS YOUR HISTORY AND ROS SEVERAL TIMES THROUGHOUT THE VISIT.
 - FOR THE SAKE OF COMPLEXITY, MR. B. HAS A CAT ASSESSMENT SCORE OF 19
- WHAT IS YOUR NEXT STEP?

CASE STUDY - TREATMENT

 YOU SEND MR. B. FOR A SCREENING CT AND SPIROMETRY, HIS CT IS CLEAR, BUT HIS SPIROMETRY SHOWS AND FEV1 46% PREDICTED (GOLD 3).

- WHAT IS/ARE YOUR FIRST LINE TREATMENT(S)?
- REMEMBER, CAT 19, MMRC 2, NO HOSPITALIZATIONS = ABE GROUP B
- YOU DISCUSS YOUR TREATMENT PLAN WITH MR. B., WHAT ELSE WOULD YOU DISCUSS WITH HIM?

CASE STUDY FOLLOW-UP

- MR. B. SHOULD FOLLOW UP IN 4-6 WEEKS TO ASSESS EFFICACY OF MEDICATIONS.
 - ALLOW 4-6 WEEKS FOR FULL EFFECT OF ICS
- CONTINUE TO FOLLOW THE TREATMENT ALGORITHM FOR CHANGING SYMPTOMS.
- TREAT SYMPTOMS, NOT TEST RESULTS.
- CONTINUE TO PROMOTE SMOKING CESSATION AND PPE FOR ENVIRONMENTAL EXPOSURES.
- REFER TO PULMONOLOGY IF NEEDED!